STA-5326 ( DrugBank: - )

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
65	原発性免疫不全症候群	1
96	クローン病	5

65. 原発性免疫不全症候群

臨床試験数 : 500 / 薬物数 : 614 - (DrugBank : 119) / 標的遺伝子数 : 92 - 標的パスウェイ数 : 217

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00263237 (ClinicalTrials.gov)	December 2, 2005	7/12/2005	STA-5326 Meslylate to Treat Gut Inflammation Associated With Common Variable Immunodeficiency	A Pilot Study of Safety and Efficacy of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency	Common Variable Immunodeficiency	Drug: STA-5326	National Institute of Allergy and Infectious Diseases (NIAID)	NULL	Completed	18 Years	75 Years	All	10	Phase 1	United States

96. クローン病

臨床試験数 : 2,442 / 薬物数 : 1,278 - (DrugBank : 248) / 標的遺伝子数 : 142 - 標的パスウェイ数 : 209

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2005-002857-29-HU (EUCTR)	04/01/2006	18/08/2005	A Randomized, Double-blind, Placebo-controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 mesylate, for the Induction of Clinical Response in Patients with Crohn’s Disease	A Randomized, Double-blind, Placebo-controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 mesylate, for the Induction of Clinical Response in Patients with Crohn’s Disease	Moderate to severe, active Crohn’s disease MedDRA version: 3.2;Level: LLT;Classification code 10011401	Product Name: STA-5326 mesylate Product Code: S38 Other descriptive name: STA-6838, STA-5326 m, S38	Synta Pharmaceutical Corporation	NULL	Not Recruiting			Female: yes Male: yes	282		Hungary
2	NCT00250198 (ClinicalTrials.gov)	November 3, 2005	5/11/2005	The Immunological and Blood Effects of STA-5326 Mesylate on Patients With Crohn's Disease	A Randomized, Double-blind, Pilot Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, to Investigate Peripheral Blood and Mucosal Mononuclear Cell Phenotype and Cytokine Responses in Patients With Crohn's Disease	Crohn's Disease	Drug: STA-5326	National Institute of Allergy and Infectious Diseases (NIAID)	NULL	Completed	18 Years	75 Years	All	12	Phase 2	United States
3	NCT00234741 (ClinicalTrials.gov)	November 2005	5/10/2005	Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease	A Randomized, Double-Blind, Pilot Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, to Investigate Peripheral Blood and Mucosal Mononuclear Cell Phenotype and Cytokine Responses in Patients With Crohn's Disease	Crohn's Disease	Drug: STA-5326 mesylate	Synta Pharmaceuticals Corp.	National Institute of Allergy and Infectious Diseases (NIAID);National Institutes of Health (NIH)	Completed	18 Years	75 Years	Both	12	Phase 2	United States
4	NCT00138840 (ClinicalTrials.gov)	August 2005	26/8/2005	Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease	A Randomized, Double-Blind, Placebo-Controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, for the Induction of Clinical Response in Patients With Crohn's Disease	Crohn's Disease	Drug: STA-5326 mesylate	Synta Pharmaceuticals Corp.	NULL	Completed	18 Years	75 Years	Both	282	Phase 2	United States;Canada
5	NCT00088062 (ClinicalTrials.gov)	February 2004	19/7/2004	STA-5326 in Crohn's Disease Patients	A Phase I/IIa Trial of STA-5326 in Crohn's Disease Patients With CDAI Scores of 220-450	Crohn's Disease	Drug: STA-5326	Synta Pharmaceuticals Corp.	NULL	Completed	18 Years	65 Years	Both	48	Phase 1/Phase 2	United States